Depomed inks licensing agreement with Ironwood

The tie up allows Ironwood to develop and commercialize the product, however Depomed will help in initial product formulation.

As per the terms of the deal, Depomed is entitled to receive upfront license fee and additional payments on achieving certain development and regulatory milestones to Ironwood.

Ironwood is also responsible to pay royalties on product sales to Depomed.

Ironwood Corporate Development vice president said they believe the Acuform technology is complementary to their internal effort to create differentiated medicines and provides Ironwood with the opportunity to continue to build a portfolio of development candidates through both internal and external R&D.